On Tuesday, Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), gained 18.38% to $19.84.
Bellicum Pharmaceuticals, stated financial results for the third quarter of 2015 and offered an update on recent developments.
“During the third quarter we continued to make good progress in the advancement of our stem cell transplant, CAR-T and TCR programs,” said Tom Farrell, President and Chief Executive Officer of Bellicum. “We are particularly excited about the interim data that will be presented at ASH 2015 that underscore the potential of our lead product candidate BPX-501 to improve outcomes for patients with blood cancers and inherited blood diseases undergoing haplo transplantation. BPX-501 could be used in the treatment of over 60 rare diseases, enabling a potential curative transplant for many of those disorders, counting sickle cell disease, where treatment-related mortality has severely limited the adoption of allogeneic transplantation.”
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally.
Shares of Toronto-Dominion Bank (NYSE:TD), inclined 1.00% to $41.39, during its last trading session.
TD Asset Administration, the manager of TD Mutual Funds, was recognized at the Canadian Lipper Awards, held last night in Toronto. The TD Health Sciences Fund - Investor Series, the TD Entertainment & Communications Fund - Investor Series, and the TD U.S. Mid-Cap Growth Fund - Investor Series took home top prizes in their respective categories.
“It’s an honour to be recognized by the Lipper Awards for the strength of our fund company,” said Tim Wiggan, Chief Executive Officer, TDAM. “These awards reflect our commitment to delivering investment excellence and long-term value to our investors. This recognition also highlights the long-standing relationship we have with T. Rowe Price Associates, Inc., sub-adviser on these three funds, and it is a tribute to our strong equity line-up,” added Wiggan.
Each of the following TD Mutual Funds was named as the top fund in their respective category over a 3, 5 or 10-year time period by Lipper.
The Toronto-Dominion Bank, together with its auxiliaries, provides financial and banking services in North America and internationally. The company operates through Canadian Retail, U.S. Retail, and Wholesale Banking segments.
Finally, Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), ended its last trade with -9.34% loss, and closed at $16.21.
Halozyme Therapeutics, stated financial results for the third quarter ended September 30, 2015. Revenue for the quarter of $20.8 million and a net loss of $24.5 million, or $0.19 per share, contrast to revenue of $14.6 million and a net loss of $20.3 million, or $0.16 per share, for the third quarter of 2014. Financial results for the quarter were in line with company expectations and its annual financial guidance, which the company reiterated recently.
“With more than 100 patients now enrolled in Stage 2 of our Phase 2 study in pancreatic cancer patients, we are on track to close enrollment by the end of the year and achieve a major milestone toward our aim of ultimately commercializing PEGPH20,” said Dr. Helen Torley, president and CEO. “Strong progress was made towards our aim of evaluating the pan tumor potential of PEGH20 by dosing the first patient in our immuno-oncology clinical trial in combination with Merck’s KEYTRUDA and by executing well on our broader clinical trial roadmap, counting planning for initiation of our Phase 3 study in pancreatic cancer at the end of the first quarter of 2016.
“At the same time, our ENHANZE technology platform continued to deliver a growing royalty revenue stream from partnershipand licensing agreements with Roche and Baxalta, and we achieved important milestones toward potential future royalties with Pfizer, Janssen and AbbVie. Further progress was demonstrated by Pfizer and Janssen who initiated dosing in separate Phase 1 clinical trials with ENHANZE, while AbbVie declared plans to work with Halozyme on HUMIRA® (adalimumab) with the aim to assist reduce the number of induction injections and deliver additional performance benefits.”
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.